Development of Optimized Tissue-Factor-Targeted Peptide Amphiphile Nanofibers to Slow Noncompressible Torso Hemorrhage
- 3 June 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (6), 6649-6662
- https://doi.org/10.1021/acsnano.9b09243
Abstract
Non-compressible torso hemorrhage accounts for a significant portion of preventable trauma deaths. We report here on the development of injectable, targeted supramolecular nanotherapeutics based on peptide amphiphile (PA) molecules that are designed to target tissue factor (TF) and, therefore, selectively localize to sites of injury to slow hemorrhage. Eight TF-targeting sequences were identified, synthesized into PA molecules, co-assembled with non-targeted backbone PA at various weight percentages, and characterized via circular dichroism spectroscopy, transmission electron microscopy, and X-ray scattering. Following intravenous injection in a rat liver hemorrhage model, two of these PA nanofiber co-assemblies exhibited the most specific localization to the site of injury compared to controls (p<0.05), as quantified using immunofluorescence imaging of injured liver and uninjured organs. To determine if the nanofibers were targeting to TF in vivo, a mouse saphenous vein laser injury model was performed and showed that TF-targeted nanofibers co-localized with fibrin, demonstrating increased levels of nanofiber at TF-rich sites. Thromboelastograms obtained using samples of heparinized rat whole blood containing TF demonstrated that no clots were formed in the absence of TF-targeted nanofibers. Lastly, both PA nanofiber co-assemblies decreased blood loss in comparison to sham and backbone nanofiber controls by 35% to 59% (p<0.05). These data demonstrate an optimal TF-targeted nanofiber that localizes selectively to sites of injury and TF exposure, and, interestingly, reduces blood loss. This research represents a promising initial phase in the development of a TF-targeted injectable therapeutic to reduce preventable deaths from hemorrhage.Keywords
Funding Information
- School of Medicine, University of North Carolina at Chapel Hill
- National Heart, Lung, and Blood Institute (1R01HL116577-01, 1R35HL144976-01)
- American Heart Association (18POST33960499)
- U.S. Department of Defense (FA8650-16-2-6G19)
- American Australian Association
- Division of Materials Research (DMR-1720139)
- International Institute for Nanotechnology, Northwestern University
- Center for Regenerative Nanomedicine, Northwestern University
- state of Illinois
This publication has 41 references indexed in Scilit:
- Intravenous Hemostatic Nanoparticles Increase Survival Following Blunt Trauma InjuryBiomacromolecules, 2012
- Functional Supramolecular PolymersScience, 2012
- Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialThe Lancet, 2010
- Self‐assembly of peptide amphiphiles: From molecules to nanostructures to biomaterialsPeptide Science, 2010
- Intravenous Hemostat: Nanotechnology to Halt BleedingScience Translational Medicine, 2009
- Irena: tool suite for modeling and analysis of small-angle scatteringJournal of Applied Crystallography, 2009
- Citrate anticoagulation and the dynamics of thrombin generationJournal of Thrombosis and Haemostasis, 2007
- Using circular dichroism spectra to estimate protein secondary structureNature Protocols, 2006
- The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factorNature, 1996
- Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and tissue factor pathway inhibitorThrombosis Research, 1995